BioPharma Drive: Drug Pricing

NOVEMBER 19, 2024

Elsewhere, former NCI director Ned Sharpless founded a new startup and Novartis licensed another radiopharma drug. The agency turned back Astellas’ attempt to update its drug Izervay’s labeling.

Licensing 139

Licensing Licensing FDA Drugs 139

Drug Patent Watch

JULY 30, 2024

The Power of Patent Licensing: Unlocking Innovation and Access to Medicines Patent licensing agreements have become a crucial tool in the pharmaceutical industry, allowing companies to collaborate and…

Licensing 105

Licensing Licensing Pharmaceuticals Drugs 105

BioPharma Drive: Drug Pricing

NOVEMBER 13, 2023

With the deal, the Swiss pharma is exploring a tumor target, DLL3, that’s thwarted past drugmaker efforts to attack it.

Licensing 183

Licensing Licensing Therapies 183

BioPharma Drive: Drug Pricing

JULY 3, 2024

The mRNA specialist plans to eliminate 30% of its workforce as part of a restructuring that will prioritize “high-value” projects like its cancer vaccines.

Vaccine 164

Vaccine Licensing Licensing 164

Drug Discovery Today

DECEMBER 2, 2020

Sanyou signs two commercial-use licenses for Horizon’s gene-edited CHO-K1 GS knockout cell line, for use in biotherapeutic pipeline development and contract research services

Licensing 113

Licensing Licensing Research 113

BioPharma Drive: Drug Pricing

MARCH 13, 2025

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic focus, executives said on a conference call.

Licensing 246

Licensing Licensing Drugs 246

BioPharma Drive: Drug Pricing

OCTOBER 22, 2024

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for its clinical-stage treatment reni-cel.

Therapies 280

Therapies Licensing Licensing Treatment 280

BioPharma Drive: Drug Pricing

MARCH 3, 2025

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer Hummingbird Bioscience.

Licensing 236

Licensing Licensing Drug Development Drugs 236

BioPharma Drive: Drug Pricing

DECEMBER 2, 2024

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.

Licensing 273

Licensing Licensing Drugs 273

BioPharma Drive: Drug Pricing

MARCH 12, 2025

Ionis’ drug, sapablursen, is currently being tested in a Phase 2 trial in patients with polycythemia vera.

Licensing 139

Licensing Licensing Disease Drugs 139

BioPharma Drive: Drug Pricing

DECEMBER 12, 2023

Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”

Drug Research 291

Drug Research Licensing Licensing Research 291

BioPharma Drive: Drug Pricing

MARCH 28, 2024

Xilio will get just over $40 million from Gilead in return for a license to its experimental IL-12 immunotherapy. The biotech is also discontinuing other work and laying off staff.

Licensing 280

Licensing Licensing Drugs 280

BioPharma Drive: Drug Pricing

FEBRUARY 8, 2024

The German biotech will invest $200 million in Autolus — funds that, along with a $50 million fee, will give it licensing opportunities and access to supply infrastructure.

Therapies 274

Therapies Licensing Licensing 274

BioPharma Drive: Drug Pricing

JANUARY 14, 2025

Nippon Shinyaku will pay Regenxbio $110 million upfront for U.S. and Asia rights to treatments for Hunter and Hurler syndromes.

Licensing 139

Licensing Licensing Therapies Treatment 139

BioPharma Drive: Drug Pricing

JANUARY 9, 2025

The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind Biosciences, led by an oral therapy ready for Phase 2 testing.

Licensing 250

Licensing Licensing Therapies Drugs 250

BioPharma Drive: Drug Pricing

MARCH 25, 2025

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a genetic risk factor called lipoprotein(a).

Licensing 207

Licensing Licensing Pharmaceuticals 207

BioPharma Drive: Drug Pricing

OCTOBER 18, 2024

European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data and Leqembi hit a roadblock in Australia.

Licensing 156

Licensing Licensing Regulations Drugs 156

BioPharma Drive: Drug Pricing

OCTOBER 2, 2024

The company will permit six generic drugmakers to make and sell lenacapavir in 120 countries that have high incidence of the disease but limited resources.

Licensing 148

Licensing Licensing Disease Drugs 148

BioPharma Drive: Drug Pricing

JUNE 8, 2023

Two-year-old Kate Therapeutics is launching publicly with $51 million in funding and a licensing deal with Astellas Pharma for a neuromuscular disease gene therapy.

Therapies 246

Therapies Disease Licensing Licensing 246

BioPharma Drive: Drug Pricing

JULY 10, 2023

The pharma company will pay $30 million upfront to gain rights to an experimental therapy meant to enhance the anti-tumor effect of radiation.

Licensing 139

Licensing Licensing Pharma Companies Treatment 139

BioPharma Drive: Drug Pricing

MARCH 3, 2025

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.

Licensing 188

Licensing Licensing Therapies Drugs 188

BioPharma Drive: Drug Pricing

DECEMBER 4, 2024

Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy.

Licensing 139

Licensing Licensing Drugs Therapies 139

BioPharma Drive: Drug Pricing

MARCH 24, 2025

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

Licensing 171

Licensing Licensing Drugs 171

BioPharma Drive: Drug Pricing

AUGUST 1, 2023

Some on Wall Street believe the New York-based biotechnology company is now less likely to get acquired after agreeing to sell partial rights to its only marketed product.

Licensing 130

Licensing Licensing Production Marketing 130

BioPharma Drive: Drug Pricing

JULY 10, 2023

The licensing agreement for the biotech’s viral vector platform follows recent Astellas agreements with Taysha Gene Therapies and Kate Therapeutics.

Therapies 215

Therapies Licensing Licensing 215

Drug Discovery Today

APRIL 22, 2020

Cambridge, UK, and Brisbane, CA, 21 April 2020 Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license (..)

Licensing 100

Licensing Licensing Engineering Therapies 100

Science Daily: Pharmacology News

AUGUST 9, 2023

The drug tecovirimat is currently in use for the treatment of mpox -- the disease caused by monkeypox virus -- that spread worldwide in 2022. Tecovirimat is an anti-poxviral drug, and its use is driving the emergence of drug-resistant variants of the monkeypox virus.

Licensing 152

Licensing Licensing Treatment Virus 152

Drug Discovery Today

JANUARY 26, 2022

a leading provider of integrated drug discovery services to life science organisations globally, is delighted that Professors Daniel Longley, Tim Harrison and colleagues at Queen’s University Belfast have entered into a collaboration and licensing agreement with Ipsen. Saffron Walden, 26th January 2022 / Domainex Ltd.,

Licensing 100

Licensing Licensing Science Research 100

Drug Discovery Today

JULY 7, 2022

Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapiesAgreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercializationAccess (..)

Licensing 100

Licensing Licensing Vaccine DNA 100

BioPharma Drive: Drug Pricing

JULY 20, 2023

The startup will take on development of a shigellosis vaccine GSK inherited when it acquired LimmaTech’s predecessor, GlycoVaxyn, in 2015.

Vaccine 130

Vaccine Licensing Licensing 130

BioPharma Drive: Drug Pricing

MAY 9, 2024

The deal gives the company milestone payments and royalties to a medicine, frexalimab, that Sanofi licensed from biotech ImmuNext and expects to be a future blockbuster.

Licensing 177

Licensing Licensing Drugs 177

BioPharma Drive: Drug Pricing

MARCH 26, 2025

The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis and Novo fine tuned its Wegovy cash-pay program.

Licensing 148

Licensing Licensing Drugs 148

BioPharma Drive: Drug Pricing

JUNE 4, 2024

The company may look to license the experimental liver disease drug as it focuses on an obesity treatment that's shown early promise.

Licensing 164

Licensing Licensing Treatment Disease 164

BioPharma Drive: Drug Pricing

JUNE 18, 2024

With a drug licensed from Novartis, the new biotech startup aims to reduce the ‘remnant’ cholesterol it says existing medicines can’t address.

Licensing 164

Licensing Licensing Drugs 164

BioPharma Drive: Drug Pricing

JULY 12, 2024

Elsewhere, Ipsen is licensing an ADC and Novartis is closing a San Diego site. Sales data suggest forecasts for the Alzheimer’s drug may be in reach.

Licensing 164

Licensing Licensing Drugs 164

BioPharma Drive: Drug Pricing

FEBRUARY 11, 2025

billion and returns to Novartis a blood thinner it licensed to the Blackstone-backed startup six years ago. The acquisition of Anthos Therapeutics could be worth up to $3.1

Licensing 164

Licensing Licensing 164

BioPharma Drive: Drug Pricing

APRIL 2, 2024

A Pfizer drug licensed to a Roivant subsidiary surpassed expectations in a type of uveitis, while a stock purchase plan will see Roivant buy out shares owned by Sumitomo Pharma.

Licensing 164

Licensing Licensing Drugs 164